Amarantus claimed that MANF is a highly potent, neurotrophic factor currently in pre-clinical development for the treatment of a range of diseases that includes Parkinson’s disease.
Amarantus said that the patent will broaden overall protection for the its therapeutic development of MANF.
Martin Cleary, CEO of Amarantus, said: “This initial patent allowance from the EPO is a major milestone for the company’s intellectual property pursuits and significantly strengthens our proprietary position in the field.
“Moreover, this latest patent will further protect Amarantus’ intellectual property as the company expands its pipeline of first-in-class therapeutics to address a number of indications.
“Additionally, we will continue to build a strong intellectual property portfolio around our proprietary technology and to further strengthen our leadership position in the emerging field of novel therapeutics.”